erdafitinib
janssen
['ragnar', 'erdafitinib']
 presenting the ragnar #asco22 - largest tumor agnostic targeted therapy phase 2 study : erdafitinib orr 29.2% dcr 72.5% in fgfr altered tumors including hard to treat cancers ! 